Frontlight ResearchEarly access
Liver and biliary tract cancer trials in China
616 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Not yet taking people in ChinaA Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma
- Where
- Guangzhou, Shanghai, Wuhan
- Age
- 18 years and over
- People
- 112
- Run by
- Shanghai 6th People's Hospital
See details and how to joinNCT07632235 - No phaseNot yet taking people in ChinaHCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B
- Where
- Beijing
- Age
- 18 years and over
- People
- 2,000
- Run by
- Beijing Friendship Hospital
See details and how to joinNCT07780357 - Phase 1/2Taking peopleA Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- Where
- Anyang, Baoding, Beijing, Bengbu, Changchun, Changsha, Changzhou, Chongqing, Guangzhou, Hangzhou, Hefei, Hongcun, Jinan, Jining, Kunming, Lanzhou, Liaocheng, Nanchang, Nanning, Shanghai, Shenyang, Tianjin, Wenzhou, Wuhan, Wuxi, Xiamen, Xi’an, Xuzhou, Yantai, Yulin, Zhengzhou, Zibo
- Age
- 18 years and over
- People
- 796 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT05150691 - Phase 2Not yet taking people in ChinaShuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome
- Where
- Hangzhou
- Age
- 18 years to 75 years
- People
- 120
- Run by
- Xiang-Qian
See details and how to joinNCT07691645 - Phase 4Not yet taking people in ChinaA Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular Invasion
- Where
- Zhengzhou
- Age
- 18 years to 80 years
- People
- 40
- Run by
- Zhai Wenlong
See details and how to joinNCT07790419 - Phase 2Taking peopleHAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma
- Where
- Wuhan
- Age
- 18 years and over
- People
- 36
- Run by
- Tongji Hospital
See details and how to joinNCT06187961 - Phase 2Taking peoplePemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma
- Where
- Beijing
- Age
- 18 years to 80 years
- People
- 154
- Run by
- Haitao Zhao, MD
See details and how to joinNCT07786766 - No phaseTaking peopleLiver Volume Metrics for Predicting Immunotherapy Prognosis in Unresectable Hepatocellular Carcinoma
- Where
- Hefei
- Age
- 18 years to 75 years
- People
- 467
- Run by
- Anhui Provincial Hospital
See details and how to joinNCT07782632 - Early phase 1Taking peopleA IIT Study of 177Lu-DOTA-SNA040
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 12
- Run by
- SmartNuclide Biopharma
See details and how to joinNCT07595237 - Phase 1Taking peopleA First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
- Where
- Jinan
- Age
- 18 years to 75 years
- People
- 299 worldwide
- Run by
- Huahui Health
See details and how to joinNCT07623369 - No phaseTaking peoplePeg IFNα-2b Therapy for Unresectable Mid to Late Stage HBV-HCC
- Where
- Nanjing
- Age
- 18 years and over
- People
- 33
- Run by
- Jinling Hospital, China
See details and how to joinNCT07769827 - No phaseTaking peopleDigital Early Warning System for Acute Lung Injury in Liver Surgery
- Where
- Beijing, Chongqing, Qingdao
- Age
- 18 years and over
- People
- 3,000
- Run by
- Beijing Tsinghua Chang Gung Hospital
See details and how to joinNCT07070362 - Phase 2Taking peopleGKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
- Where
- Beijing, Changsha, Hangzhou, Nanchang, Nanjing, Zhengzhou
- Age
- 18 years to 80 years
- People
- 48
- Run by
- Beijing Gene Key Life Technology Co., Ltd
See details and how to joinNCT07209813 - No phaseNot yet taking people in ChinaPragmatic RCT of AI-Assisted Reading for Malignant Hepatic Lesions on CE-CT
- Where
- Shenyang
- Age
- 18 years and over
- People
- 40,000
- Run by
- Shengjing Hospital
See details and how to joinNCT07768085 - Phase 1Taking peopleYMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic Malignancies
- Where
- Chengdu
- Age
- 18 years to 75 years
- People
- 9
- Run by
- West China Hospital
See details and how to joinNCT07763301 - No phaseTaking peopleProtective Mechanisms of Phycocyanin in Partial Hepatectomy-Associated Liver Injury
- Where
- Hangzhou
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07760038 - Phase 1/2Not yet taking people in ChinaEvaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma
- Where
- Harbin
- Age
- 18 years and over
- People
- 288
- Run by
- CSPC Megalith Biopharmaceutical Co.,Ltd.
See details and how to joinNCT07761286 - Phase 2Taking peopleLenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 320
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT06904183 - No phaseTaking peopleThe Safety, Efficacy, and Immune Response of Multimodal Thermal Therapy in the Treatment of Malignant Liver Tumors
- Where
- Shanghai
- Age
- 18 years to 80 years
- People
- 120
- Run by
- Fudan University
See details and how to joinNCT07159048 - Phase 2Not yet taking people in ChinaSHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma
- Where
- Langfang
- Age
- 18 years to 75 years
- People
- 80
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07749859 - Phase 3Taking peopleA Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence
- Where
- Tianjin
- Age
- 18 years to 75 years
- People
- 198
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07475026 - Phase 2Taking peopleThe Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities
- Where
- Wenzhou
- Age
- 18 years to 80 years
- People
- 134
- Run by
- First Affiliated Hospital of Wenzhou Medical University
See details and how to joinNCT07381634 - No phaseTaking peopleIntelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular Carcinoma
- Where
- Wenzhou
- Age
- 18 years and over
- People
- 400
- Run by
- First Affiliated Hospital of Wenzhou Medical University
See details and how to joinNCT07495735 - No phaseTaking peopleModified Single-Incision Plus One-Port Versus Conventional Five-Port Laparoscopic Pancreaticoduodenectomy for Nonpancreatic Periampullary Adenocarcinomas
- Where
- Chengdu, Chongqing, Guangzhou, Jiancheng
- Age
- 18 years to 75 years
- People
- 232
- Run by
- Nanfang Hospital, Southern Medical University
See details and how to joinNCT07744087 - Phase 2Not yet taking people in ChinaSafety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer
- Where
- Shanghai
- Age
- 18 years and over
- People
- 20
- Run by
- Ruijin Hospital
See details and how to joinNCT07745790